Taflan 1.5 mg/100 ml Eye Drop

Elevated Intraocular Pressure

Drugs for miotics and glaucoma

Tafluprost, a prostaglandin analog is a selective FP prostanoid receptor agonist which is believed to reduce intraocular pressure by increasing uveoscleral outflow of aqueous humor.

Administration: Instill into conjunctival sac of affected eye(s) Do not exceed once daily dosing regimen; more frequent administration of prostaglandin analogs may lessen the IOP lowering effect Reduction of intraocular pressure starts approximately 2 - 4 hours after first administration with maximum effect reached after 12 hr If other topical ophthalmics are prescribed, each should be administered 5 minutes apart Adult Dose: Elevated Intraocular Pressure Indicated for reducing elevated IOP in patients with open-angle glaucoma or ocular hypertension Instill 1 drop in affected eye(s) once daily in the evening

Tafluprost ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product.

>10% Conjunctival hyperemia (4-20%) 1-10% Ocular stinging (7%),Ocular pruritus/allergic conjunctivitis (5%),Cataract (3%),Growth of eyelashes (2%),Blurred vision (2%)

Use in pregnancy: Pregnancy category C. There are no adequate and well-controlled studies in pregnant women. Tafluprost ophthalmic solution should be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.Use in lactation: It is not known whether Tafluprost is excreted in human milk. Caution should be exercised while giving this ophthalmic solution to a nursing mother.

Precaution: Causes changes to pigmented tissues; most frequently reported changes have been of the iris, eyelid, and eyelashes; pigmentation changes of the iris is likely permanent Increases length, color, thickness, and number of eyelashes Caution with active intraocular inflammation (may exacerbate condition) Macular edema reported; caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema. Lactation: Unknown whether distributed in breast milk.

Drugs for miotics and glaucoma

Prostaglandin analog; exact mechanism by which it reduces IOP is unknown, but it is thought to increase uveoscleral outflow

Use in pregnancy: Pregnancy category C. There are no adequate and well-controlled studies in pregnant women. Tafluprost ophthalmic solution should be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.Use in lactation: It is not known whether Tafluprost is excreted in human milk. Caution should be exercised while giving this ophthalmic solution to a nursing mother.

Related Medicines

Save Medicine to Collection

Taflan 1.5 mg/100 ml

Create New Collection